脓毒症危重患者中连续与间断给予美罗培南的比较:MERCY随机临床试验
该双盲随机临床试验在4个国家26家医院31个ICU纳入607例脓毒症或脓毒性休克患者,比较连续与间断输注美罗培南对28天全因死亡和泛耐药或广泛耐药菌出现的复合结局的影响。连续组主要结局发生率47%,间断组49%,相对风险0.96(95%CI 0.81-1.13,P=0.60),差异无统计学意义;4项次要结局均无统计学显著性,90天死亡率两组均为42%。
要点
- 在脓毒症危重患者中,连续输注美罗培南未改善28天死亡与耐药菌出现的复合结局。
- 主要结局连续组47% vs 间断组49%,相对风险0.96(95%CI 0.81-1.13,P=0.60)。
- 4项次要结局均无统计学显著性,90天死亡率两组均为42%。
核心结论
- 在脓毒症危重患者中,与间断给药相比,连续给予美罗培南未改善28天死亡和泛耐药或广泛耐药菌出现的复合结局。
研究设计与样本
- 双盲随机临床试验,纳入4个国家(克罗地亚、意大利、哈萨克斯坦和俄罗斯)26家医院31个ICU中由治疗医生开具美罗培南的脓毒症或脓毒性休克危重患者,2018年6月5日至2022年8月9日入组,2022年11月完成90天随访。
- 患者随机接受等剂量美罗培南连续给药(n=303)或间断给药(n=304),共607例(平均年龄64岁[SD 15],女性203例[33%])。
主要发现
- 主要结局(28天全因死亡和泛耐药或广泛耐药菌出现的复合结局)连续给药组142例(47%)vs 间断给药组149例(49%),相对风险0.96(95%CI 0.81-1.13,P=0.60)。
- 4项次要结局均无统计学显著性。
- 90天死亡率连续给药组42%(127/303)与间断给药组42%(127/304)相同。
- 未报告与研究药物相关的癫痫发作或过敏反应不良事件。
- 369例(61%)为脓毒性休克,从入院至随机化的中位时间为9天(IQR 3-17天),美罗培南治疗中位时间为11天(IQR 6-17天),仅记录到1例交叉事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Meropenem is a widely prescribed β-lactam antibiotic. Meropenem exhibits maximum pharmacodynamic efficacy when given by continuous infusion to deliver constant drug levels above the minimal inhibitory concentration. Compared with intermittent administration, continuous administration of meropenem may improve clinical outcomes. OBJECTIVE: To determine whether continuous administration of meropenem reduces a composite of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria compared with intermittent administration in critically ill patients with sepsis. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized clinical trial enrolling critically ill patients with sepsis or septic shock who had been prescribed meropenem by their treating clinicians at 31 intensive care units of 26 hospitals in 4 countries (Croatia, Italy, Kazakhstan, and Russia). Patients were enrolled between June 5, 2018, and August 9, 2022, and the final 90-day follow-up was completed in November 2022. INTERVENTIONS: Patients were randomized to receive an equal dose of the antibiotic meropenem by either continuous administration (n = 303) or intermittent administration (n = 304). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28. There were 4 secondary outcomes, including days alive and free from antibiotics at day 28, days alive and free from the intensive care unit at day 28, and all-cause mortality at day 90. Seizures, allergic reactions, and mortality were recorded as adverse events. RESULTS: All 607 patients (mean age, 64 [SD, 15] years; 203 were women [33%]) were included in the measurement of the 28-day primary outcome and completed the 90-day mortality follow-up. The majority (369 patients, 61%) had septic shock. The median time from hospital admission to randomization was 9 days (IQR, 3-17 days) and the median duration of meropenem therapy was 11 days (IQR, 6-17 days). Only 1 crossover event was recorded. The primary outcome occurred in 142 patients (47%) in the continuous administration group and in 149 patients (49%) in the intermittent administration group (relative risk, 0.96 [95% CI, 0.81-1.13], P = .60). Of the 4 secondary outcomes, none was statistically significant. No adverse events of seizures or allergic reactions related to the study drug were reported. At 90 days, mortality was 42% both in the continuous administration group (127 of 303 patients) and in the intermittent administration group (127 of 304 patients). CONCLUSIONS AND RELEVANCE: In critically ill patients with sepsis, compared with intermittent administration, the continuous administration of meropenem did not improve the composite outcome of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03452839.
引用
- Monti G, Bradic N, Marzaroli M, et al. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. JAMA. 2023. PMID: 37326473. doi:10.1001/jama.2023.10598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。